S. Meuth

发表

Pervasive head-to-tail insertions of DNA templates mask desired CRISPR/Cas9-mediated genome editing events

J. Brosius, Y. Schwartz, S. Meuth, 2019, bioRxiv.

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study

M. Pawlitzki, T. Ruck, Niklas Huntemann, 2023, Neurological Research and Practice.

A study of the geographic accessibility of outpatient memory clinics in Germany

E. Düzel, J. Repple, M. Pawlitzki, 2023, Deutsches Ärzteblatt international.

Plasminogen Activator Inhibitor-1 Antagonist TM 5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis

Douglas, T. Miyata, D. Vaughan, 2015 .

TPP2 mutation associated with sterile brain inflammation mimicking MS

T. Wieland, A. Deutschländer, T. Strom, 2018, Neurology: Genetics.

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19

F. Zipp, H. Wiendl, S. Meuth, 2021, Neurology: Neuroimmunology & Neuroinflammation.

Calcium Homeostasis in Multiple Sclerosis

S. Meuth, Petra Hundehege, Lisa Epping, 2017, Neurology International Open.

Integrative-interpersonal dynamic therapy for poststroke depression (INID): study protocol of a randomised controlled pilot trial

K. Werheid, B. Wild, J. Barber, 2023, BMJ open.

S1PR-1/5 modulator RP-101074 shows beneficial effects in a model of central nervous system degeneration

T. Ruck, Christina Hecker, Michael Dietrich, 2023, Frontiers in immunology.

Blend Sign and Haemorrhage Location and Volume Predict Late Recurrence and Mortality in Intracerebral Haemorrhage Patients

M. Luchtmann, S. Vielhaber, F. Schreiber, 2023, Journal of clinical medicine.

Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review

T. Ziemssen, S. Meuth, C. Stadelmann, 2015, PloS one.

TRPC6 channels modulate the response of pancreatic stellate cells to hypoxia

I. Kovalenko, Sven Christian, S. Meuth, 2017, Pflügers Archiv - European Journal of Physiology.

Platelets and vascular inflammation of the brain

S. Meuth, H. Langer, C. Kleinschnitz, 2015, Hämostaseologie.

Disease‐modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies

N. Melzer, S. Meuth, S. Meuth, 2014, Clinical and experimental immunology.

Multiple sclerosis therapy: An update on recently finished trials

H. Wiendl, S. Meuth, B. Kieseier, 2007, Journal of Neurology.

International Journal of Molecular Sciences the Inflammatory Role of Platelets: Translational Insights from Experimental Studies of Autoimmune Disorders

S. Meuth, H. Langer, S. Bittner, 2022 .

Standardizing the analysis of conditioned fear in rodents: a multidimensional software approach

M. Herty, H. Pape, T. Seidenbecher, 2013, Genes, brain, and behavior.

Therapeutic Advances in Neurological Disorders

H. Wiendl, S. Meuth, T. Ruck, 2016 .

Targeting B cells in relapsing–remitting multiple sclerosis: from pathophysiology to optimal clinical management

T. Ruck, S. Bittner, H. Wiendl, 2017, Therapeutic advances in neurological disorders.

Developmental endothelial locus-1 (Del-1) is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination

E. Chavakis, S. Meuth, K. Bdeir, 2014, Molecular Psychiatry.

Chronic Fatigue and Dysautonomia following COVID-19 Vaccination Is Distinguished from Normal Vaccination Response by Altered Blood Markers

M. Uhrberg, K. Schulze-Forster, F. Boege, 2023, Vaccines.

Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases

C. Preusse, F. Kleefeld, Christopher Nelke, 2024, Acta neuropathologica.

K2P2.1 is a regulator of inflammatory cell responses in idiopathic inflammatory myopathies.

M. Pawlitzki, T. Ruck, C. Preusse, 2023, Journal of autoimmunity.

Risk factors for intracerebral hemorrhage in small-vessel disease and non-small-vessel disease etiologies—an observational proof-of-concept study

M. Pawlitzki, S. Vielhaber, Philipp Arndt, 2024, Frontiers in neurology.

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials

J. Ingwersen, S. Meuth, L. Masanneck, 2023, Scientific reports.

Current Biomarker Strategies in Autoimmune Neuromuscular Diseases

T. Ruck, Christopher Nelke, Christina B. Schroeter, 2023, Cells.

[Digital medicine in neurological research-Between hype and evidence].

M. Pawlitzki, S. Meuth, L. Masanneck, 2023, Der Nervenarzt.

Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?

T. Skripuletz, S. Meuth, Ralf Gold, 2024, Therapeutic advances in neurological disorders.

Moyamoya disease in Southeast Asians: genetic and autopsy data, new cases, systematic review, and meta-analysis of all patients from the literature

M. Kraemer, D. Strunk, J. Schwitalla, 2024, Journal of neurology.

Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort

M. Mühlau, V. Fleischer, F. Zipp, 2023, Therapeutic advances in neurological disorders.

Long-term effects of dalfampridine in patients with multiple sclerosis

H. Wiendl, S. Meuth, T. Ruck, 2014, Journal of the Neurological Sciences.

Deterministic programming of human pluripotent stem cells into microglia facilitates studying their role in health and disease

D. Schafflick, M. Heming, L. Vallier, 2022, Proceedings of the National Academy of Sciences of the United States of America.